- Home
- Publications
- Publication Search
- Publication Details
Title
PharmGKB summary
Authors
Keywords
-
Journal
Pharmacogenetics and Genomics
Volume 22, Issue 9, Pages 695-708
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2012-04-27
DOI
10.1097/fpc.0b013e3283540217
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource
- (2011) Ellen M McDonagh et al. Biomarkers in Medicine
- Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
- (2011) K-p Kim et al. BRITISH JOURNAL OF CANCER
- CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
- (2011) S R Park et al. BRITISH JOURNAL OF CANCER
- Nicotine Metabolite Ratio Predicts Smoking Topography and Carcinogen Biomarker Level
- (2011) A. A. Strasser et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age
- (2011) Z Desta et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Association between Cancer Risk and Drug-metabolizing Enzyme Gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1 and GSTT1) Polymorphisms in Cases of Lung Cancer in Japan
- (2011) Yuichiro Tamaki et al. Drug Metabolism and Pharmacokinetics
- Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women
- (2011) Hiromi Tanii et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Relationship Between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 Variation and Smoking Behaviors and Lung Cancer Risk
- (2011) Catherine A. Wassenaar et al. JNCI-Journal of the National Cancer Institute
- PharmGKB summary
- (2011) Caroline F. Thorn et al. Pharmacogenetics and Genomics
- The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European–Americans
- (2011) Joseph Bloom et al. Pharmacogenetics and Genomics
- Association analysis ofCYP2A6genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes
- (2011) Huijuan Wang et al. PHARMACOGENOMICS
- Genome-wide association study of smoking behaviours in patients with COPD
- (2011) M. Siedlinski et al. THORAX
- Associations of CYP2A6 genotype with smoking behaviors in southern China
- (2010) Tao Liu et al. ADDICTION
- The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients
- (2010) Lan Tan et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Genetic Variation in Nicotine Metabolism Predicts the Efficacy of Extended-Duration Transdermal Nicotine Therapy
- (2010) C Lerman et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population
- (2010) Natasa Djordjevic et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Molecular and Therapeutic Potential and Toxicity of Valproic Acid
- (2010) Sébastien Chateauvieux et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Liu Wei Di Huang Wan, a well-known traditional Chinese medicine, induces CYP1A2 while suppressing CYP2A6 and N-acetyltransferase 2 activities in man
- (2010) Yao Chen et al. JOURNAL OF ETHNOPHARMACOLOGY
- Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior
- (2010) Thorgeir E Thorgeirsson et al. NATURE GENETICS
- Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer
- (2010) Hirose ONCOLOGY REPORTS
- Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients
- (2010) Laure Elens et al. PHARMACOGENOMICS
- Genetic Polymorphism and Toxicology—With Emphasis on Cytochrome P450
- (2010) Inger Johansson et al. TOXICOLOGICAL SCIENCES
- Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism
- (2010) N. Al Koudsi et al. XENOBIOTICA
- CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
- (2009) Awewura Kwara et al. AIDS
- CYP2B6(c.516G→T) andCYP2A6(*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients
- (2009) Awewura Kwara et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro
- (2009) Seongwook Jeong et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genetic Associations of 115 Polymorphisms with Cancers of the Upper Aerodigestive Tract across 10 European Countries: The ARCAGE Project
- (2009) C. Canova et al. CANCER RESEARCH
- Association of Nicotine Metabolite Ratio and CYP2A6 Genotype With Smoking Cessation Treatment in African-American Light Smokers
- (2009) MK Ho et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals
- (2009) M Arab-Alameddine et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Polymorphic Drug Metabolism in Anaesthesia
- (2009) Juan Restrepo et al. CURRENT DRUG METABOLISM
- Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6
- (2009) Yuan Di et al. CURRENT DRUG METABOLISM
- A review of smoking behavior and smokers evidence (chemical modification, inducing nicotine metbolism, and individual variations by genotype: dopaminergic function and personality traits)
- (2009) Kazuhiko Iwahashi et al. DRUG AND CHEMICAL TOXICOLOGY
- Efavirenz in the therapy of HIV infection
- (2009) Natella Y Rakhmanina et al. Expert Opinion on Drug Metabolism & Toxicology
- Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment
- (2009) Cristina Rodriguez-Antona et al. HUMAN GENETICS
- CYP2B6Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port‐au‐Prince, Haiti
- (2009) Paul Leger et al. JOURNAL OF INFECTIOUS DISEASES
- Pharmacogenetics of antimalarial drugs: effect on metabolism and transport
- (2009) Reinhold Kerb et al. LANCET INFECTIOUS DISEASES
- In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
- (2009) Julia di Iulio et al. Pharmacogenetics and Genomics
- Association ofCYP2A6polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer
- (2009) Sun-Young Kong et al. PHARMACOGENOMICS
- A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo
- (2009) Nael Al Koudsi et al. PHARMACOGENOMICS JOURNAL
- Pharmacokinetic and Toxicological Profile of Artemisinin Compounds: An Update
- (2009) Bikash Medhi et al. PHARMACOLOGY
- Phase I Metabolic Genes and Risk of Lung Cancer: Multiple Polymorphisms and mRNA Expression
- (2009) Melissa Rotunno et al. PLoS One
- Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes
- (2009) K. Murai et al. XENOBIOTICA
- CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1
- (2008) Ken-ichi Fujita et al. CANCER SCIENCE
- The CYP2A6*4 Allele Is Determinant of S-1 Pharmacokinetics in Japanese Patients With Non-small-cell Lung Cancer
- (2008) Y Kaida et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
- (2008) M. I. Veiga et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens
- (2008) Doaa A. Elsherbiny et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine
- (2008) Takuro Endo et al. Pharmacogenetics and Genomics
- A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent
- (2008) Man Ki Ho et al. Pharmacogenetics and Genomics
- CYP2A6polymorphisms and risk for tobacco-related cancers
- (2008) Ana Rossini et al. PHARMACOGENOMICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started